Browsing by Author "Sanz, Ferran"

Sort by: Order: Results:

  • López-Massaguer, Oriol; Sanz, Ferran; Pastor Maeso, Manuel (Oxford University Press, 2018)
    SUMMARY: We describe an application (Collector) for obtaining series of compounds annotated with bioactivity data, ready to be used for the development of quantitative structure-activity relationships (QSAR) models. The ...
  • Bauer-Mehren, Anna; van Mulligen, Erik M.; Avillach, Paul; Carrascosa Baena, María Carmen, 1972-; García Serna, Ricard; Piñero González, Janet, 1977-; Singh, Barat; Lopes, Pedro; Oliveira, José Luis; Diallo, Gayo; Ahlberg Helgee, Ernst; Boyer, Scott; Mestres i López, Jordi; Sanz, Ferran; Kors, Jan A.; Furlong, Laura I., 1971- (Public Library of Science (PLoS), 2012)
    Drug safety issues pose serious health threats to the population and constitute a major cause of mortality worldwide. Due to the prominent implications to both public health and the pharmaceutical industry, it is of great ...
  • Flachner, Beáta; Lorincz, Zsolt; Carotti, Angelo; Nicolotti, Orazio; Kuchipudi, Praveena; Kuchipudi, Praveena; Remez Vinogradov, Nikita, 1985-; Sanz, Ferran; Tóvári, József; Szabo, Miklós J; Bertók, Béla; Cseh, Sándor; Mestres i López, Jordi; Dormán, György (Public Library of Science (PLoS), 2012)
    A novel chemocentric approach to identifying cancer-relevant targets is introduced. Starting with a large chemical collection, the strategy uses the list of small molecule hits arising from a differential cytotoxicity ...
  • Gutiérrez Sacristán, Alba; Bravo Serrano, Àlex, 1984-; Giannoula, Alexia; Mayer, Miguel Ángel, 1960-; Sanz, Ferran; Furlong, Laura I., 1971- (Oxford University Press, 2018)
    MOTIVATION: The study of comorbidities is a major priority due to their impact on life expectancy, quality of life and healthcare cost. The availability of electronic health records (EHRs) for data mining offers the ...
  • Leis Machin, Angela; Ronzano, Francesco; Mayer, Miguel Ángel, 1960-; Furlong, Laura I., 1971-; Sanz, Ferran (JMIR Publications, 2019)
    Background: Mental disorders have become a major concern in public health, and they are one of the main causes of the overall disease burden worldwide. Social media platforms allow us to observe the activities, thoughts, ...
  • Pastor Maeso, Manuel; Quintana, Jordi; Sanz, Ferran (Frontiers Media, 2018)
    In silico methods are increasingly being used for assessing the chemical safety of substances, as a part of integrated approaches involving in vitro and in vivo experiments. A paradigmatic example of these strategies is ...
  • Al-Shorbaji, N.; Bellazzi, R.; Gonzalez Bernaldo de Quiros, F.; Koch, Stefanie; Kulikowski, C. A.; Lovell, N.; Maojo, V.; Park, A.; Sanz, Ferran; Sarkar, I. N.; Tanaka, H. (Schattauer, 2016)
    This article is part of a For-Discussion-Section of Methods of Information in Medicine about the paper "The New Role of Biomedical Informatics in the Age of Digital Medicine" written by Fernando J. Martin-Sanchez and ...
  • Queralt Rosinach, Núria; Piñero González, Janet, 1977-; Bravo Serrano, Àlex, 1984-; Sanz, Ferran; Furlong, Laura I., 1971- (Oxford University Press , 2016)
    MOTIVATION: DisGeNET-RDF makes available knowledge on the genetic basis of human diseases in the Semantic Web. Gene-disease associations (GDAs) and their provenance metadata are published as human-readable and machine-processable ...
  • Piñero González, Janet, 1977-; Bravo Serrano, Àlex, 1984-; Queralt Rosinach, Núria; Gutiérrez Sacristán, Alba; Déu Pons, Jordi; Centeno, Emilio; García-García, Javier, 1982-; Sanz, Ferran; Furlong, Laura I., 1971- (Oxford University Press, 2017)
    The information about the genetic basis of human diseases lies at the heart of precision medicine and drug discovery. However, to realize its full potential to support these goals, several problems, such as fragmentation, ...
  • Piñero González, Janet, 1977-; Queralt Rosinach, Núria; Bravo Serrano, Àlex, 1984-; Déu Pons, Jordi; Bauer-Mehren, Anna; Baron, Martin; Sanz, Ferran; Furlong, Laura I., 1971- (Oxford University Press, 2015)
    DisGeNET is a comprehensive discovery platform designed to address a variety of questions concerning the genetic underpinning of human diseases. DisGeNET contains over 380,000 associations between >16,000 genes and 13,000 ...
  • Coloma, Preciosa M.; Furlong, Laura I., 1971-; Bauer-Mehren, Anna; Sanz, Ferran; Mestres i López, Jordi; Sturkenboom, Miriam (Public Library of Science (PLoS), 2013)
    Background: Drug-related adverse events remain an important cause of morbidity and mortality and impose huge burden on healthcare costs. Routinely collected electronic healthcare data give a good snapshot of how drugs are ...
  • Martí Solano, Maria; Sanz, Ferran; Pastor Maeso, Manuel; Selent, Jana (Public Library of Science (PLoS), 2014)
    Functional selectivity is a property of G protein-coupled receptors that allows them to preferentially couple to particular signaling partners upon binding of biased agonists. Publication of the X-ray crystal structure of ...
  • Cases, Montserrat; Briggs, Katharine; Steger-Hartmann, Thomas; Pognan, François; Marc, Philippe; Kleinöder, Thomas; Schwab, Christof H.; Pastor Maeso, Manuel; Wichard, Jörg; Sanz, Ferran (MDPI, 2014)
    The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug development, which follows numerous strict guidelines, are mostly not available in the public domain. These safety data ...
  • Carrió, Pau; López, Oriol; Sanz, Ferran; Pastor Maeso, Manuel (BioMed Central , 2015)
    BACKGROUND: Computational models based in Quantitative-Structure Activity Relationship (QSAR) methodologies are widely used tools for predicting the biological properties of new compounds. In many instances, such models ...
  • Mayer Pujadas, Miguel Ángel (Universitat Pompeu Fabra, 2006-11-02)
    La utilització d'Internet com a font d'informació sanitària és molt freqüent. La qualitat d'aquesta informació és extraordinàriament variable. Els segells de qualitat presents a les webs mediques, concedits per sistemes ...
  • Jiménez, Rafael C.; Sanz, Ferran; Crouch, Steve (F1000Research, 2017)
    Scientific research relies on computer software, yet software is not always developed following practices that ensure its quality and sustainability. This manuscript does not aim to propose new software development best ...
  • Bauer-Mehren, Anna; Furlong, Laura I., 1971-; Rautschka, Michael; Sanz, Ferran (BioMed Central, 2009)
    Background: Single nucleotide polymorphisms (SNPs) are the most frequent type of sequence variation between individuals, and represent a promising tool for finding genetic determinants of complex diseases and understanding ...
  • Lopes, Pedro; Nunes, Tiago; Campos, David; Furlong, Laura I., 1971-; Bauer-Mehren, Anna; Sanz, Ferran; Carrascosa Baena, María Carmen, 1972-; Mestres i López, Jordi; Kors, Jan A.; Singh, Barat; van Mulligen, Erik M.; van der Lei, Johan; Diallo, Gayo; Avillach, Paul; Ahlberg Helgee, Ernst; Boyer, Scott; Díaz, Carlos; Oliveira, José Luis (Public Library of Science (PLoS), 2013)
    Pharmacovigilance plays a key role in the healthcare domain through the assessment, monitoring and discovery of interactions amongst drugs and their effects in the human organism. However, technological advances in this ...
  • Mayer, Miguel Ángel, 1960-; Bundschus, Markus; Rautschka, Michael; Sanz, Ferran; Furlong, Laura I., 1971- (Public Library of Science (PLoS), 2011)
    Abstract/nBACKGROUND: Scientists have been trying to understand the molecular mechanisms of diseases to design preventive and therapeutic strategies for a long time. For some diseases, it has become evident that it is not ...
  • López Massaguer, Oriol, 1972-; Pinto Gil, Kevin; Sanz, Ferran; Amberg, Alexander; Anger, Lennart T; Stolte, Manuela; Ravagli, Carlo; Marc, Philippe; Pastor Maeso, Manuel (Oxford University Press, 2018)
    Over the past decades, pharmaceutical companies have conducted a large number of high-quality in vivo repeat-dose toxicity (RDT) studies for regulatory purposes. As part of the eTOX project, a high number of these studies ...